We developed a chemiluminescent enzyme immunoassay (cLEIA) to quantify such tumor markers as carcinoembryonic antigen (CEA), a-fetoprotein (AFP), CA19-9, and CAl 25. We used a novel chemiluminescent substrate, a derivative of 1,2-dioxetane phosphate (AMPPD),to measure alkaline phosphatase as a labeling enzyme to Fab' fragments of antibody. Regardless of the solid ..phase, i.e., polystyrene beads (6 mm diameter) or ferrite-coated particles (0.3 m diameter), the standard curves within the dynamic ranges of the conventional RIA or enzyme immunoassay (EIA) were linear in all cases except for those with AFP. Use of the ferrite particles further shortens the immunoreaction, so the assay can be performed in 30 mm.
malignant tumors, i.e., colorectal carcinoma, hepatoma, and pancreatic and ovarian cancers, respectively. Methods for detecting these markers in serum are mainly based on either conventional colorimetric or radiometric techniques (2, 3, 5, 8, 11) .
Recently, highly sensitive methods for immunoassay have been based on the use of chemiluminescent molecules such as luminol in an enhanced system involving phenol derivatives (12) and acridinium ester as a label for antibody (13). Bronstein (14) . The use of the AMPPD has been reported in an ultra-sensitive determination of thyrotropin and in DNA probing (14) (15) (16) .
For sensitive and rapid enzyme immunoassays (EIAs), two main factors are of great importance: affinity of antibody and activity of enzyme, which contribute to the equilibrium of the immunoreaction and to the rates of enzyme-catalyzed reactions, respectively.
A fast way for an immunoreaction to reach equilibrium involves the use of small particles of chromium dioxide (17). Here we describe rapid and sensitive assays for detecting tumor markers by using AMPPD in combination with small ferrite-coated particles.
MaterIals and Methods Materials
Antibodies: Monoclonal antibodies (MoAbs), 1116NS19-9(6-8) to CA19-9 and 0C125(9-11) to CA125, were obtained from Centocor, Malvern, PA, via Toray-Fuji Bionics, Inc., Tokyo, Japan. MoAbs AFP-8,9 to AFP and KE-2 and F1B3 to CEA were produced in mouse ascites in accordance with a conventional procedure (18) and purified from the 50%-saturated ammomum sulfate precipitates of the ascites by affinity chromatography on Affigel Protein A-agarose (Bio-Rad Labs., Hercules, CA), with elution by 0.1 mol/L acetate buffer, pH 4.2.
Antibody-coated beads or ferrite particles: Polystyrene beads (6 mm diameter; Meiwafusso Corp., Osaka, Japan) or ferrite particles (0.3 pm diameter, Nippon Paint Co., Ltd., Tokyo, Japan) were coated with antibodies (1116NS19-9, 0C125, AFP-9, or KE-2), 0.5 g/L in 50 mmol/L phosphate buffer, pH 2-4.5, for 30 min-2 h at ambient temperature.
Afterwards, we coated the beads or the ferrite particles with bovine serum albumin (BSA; Oriental Yeast Co., Ltd., Tokyo, Japan), 20 g/L, in 0.1 mol/L Ths-buffered saline for 12- Comparison methods: One EIA (CEA, Abbott kit) and three RIAs (AFP, Abbott kit, and CA19-9/CA125, Centocor kits) were used for method comparison studies.
Procedure
The principles of the sandwich assay we used are based on two-site immunometric reactions (Figure 1 The one-step, the delayed one-step, and the two-step assays correspond to simultaneous, reverse, and forward sandwich assays, respectively (22) . For the CEA and AFP assays, we used two different MoAbs. Because antigen molecules of CA19-9 or CA125 possess multiple antibody-binding sites with identical epitopes, one MoAb was used for their assay (8,11). The assay format was based on optimized conditions, determined for the individual analyte.
For the assay with the polystyrene beads, we used the one-step method for AFP or CEA (30 mm for the immunological reaction plus 20 miii for the enzyme reaction) and the two-step method for CA19-9 or CA125 (40-67 mm plus 20 mm, respectively).
We incubated 10 pL of each serum or standard with a bead that had been coated with capture antibodies. The chemiluminescent light emission was measured for 5s with a Berthold LB-9501 luminometer from the laboratory of Dr. A. Berthold, Wildbad, F.R.G.
For the assay with ferrite particles, the total assay time was 30 miii or less for all markers. The delayed one-step method for CA125 or CEA was as follows: we incubated 30 pL of serum or standard for 10 mm with 30 pL of the OC125Fab'-ALP conjugates, or 150 p1.,of the F1B3Fab'-ALP conjugates. We then transferred 20 pL of the CA125 mixture (or 60 pL for CEA) into the test tube in which 250 pL of the ferrite particles coated with the appropriate capture antibodies (0.2-0.4 g/L) had been placed and then incubated for another 10 mm. After washing the ferrite particles three or four times with isotonic saline, we added 300 .tL of the AMPPD solution. During the washing steps, the ferrite particles were magnetically separated from bulk solution on the wall of the test tube under -2000 G of magnetic field strength. After the enzyme reaction had proceeded for 5 miii, the chemiluminescent light emission was measured for 5s with a Model BLR-201 luminometer (Aloka Co., Ltd., Tokyo, Japan).
The two-step method for CA19-9 or AFP with ferrite particles was as follows: we mixed 20 pL of serum or standard with 250 pL of ferrite particle suspension (0.2-0.4 g/L) and incubated the mixture for 10 mm. After washing the ferrite particles with saline three or analyses. conjugates, and 5 mm with ANPPO for both assays Precision: We repeatedly measured the concentration of analytes in three human sera for each of the markers.
Interference:
Interference by hemolysis, lipemia, and bilirubin was examined by blending intermediate concentrations of the analyte in serum continirtg no interfering substances with increasing amounts of hemolytic solution (hemoglobin up to 11 g/L); lipemic solution artificially prepared by the manufacturer and consisting of neutral fat, phospholipid, and free fatty acid (up to 2.1 g/L, 2.3 g/L, and 620 pmol/L, respectively); or icteric solution (bilirubin up to 0.55 g/L, of which 0.36 g/L was free and 0.19 g/L was in bound form), respectively. These interfering materials were from International Reagents Corp., Kobe, Japan.
Sensitivity:
The lower limit of detection (mean +2 SD of results for the zero standard) was calculated from assay of six replicates of the zero standard. For the one-step ELA method for CEA and AFP, we determined the detection limits by using Fujirebio's commercial kits and performing the assay according to the manufacturers instructions.
These involved using 6-mm-diameter polystyrene beads as solid support and horseradish peroxidase as the enzyme label for Fab' fragments of AFP or CEA antibodies, the same as the ones used for the CLE!A, and 2,2'-azinobis(3-ethylbenzothiazoline-6-sulfonic acid) diammonium salt. Serum dilutions in the reaction system were as follows: CLEIA, 1:13.5 for CA19-9 and AFP, 1:27 for CA125, and 1:31 for CEA; EIA, 1:4 for CEA and 1:15 for AFP; RIA, 1:2 for CA19-9 and CA125 (8, 11).
All assays were performed at ambient temperature (23-27 #{176}C). Unless otherwise stated, the experimental data points in this study are the mean of duplicate
Results

Assay Optimization
Within the measurable ranges for ordinary RIA or EIA of the tumor markers (RIA: 0 to 240 kilo-arb. units/Is for CA19-9, 0 to 500 kilo-arb. unmts/Lfor CA125, and 0 to 700 pg/L for AFP; EIA: 0 to 100 pg/L for CEA), results for CLEIA performed with the bead showed a good linear relationship between analyte concentration and the intensity of chemiluminescent light emission (RLU) for all markers except AFP (data not shown). The standard curve for AFP was linear up to 100 pg/L, then declined. A typical intra-assay CV for assay of AFP was 5.7% at 2.5 pg/L (n = 4) and 1.7% at 5.0 pg/L (n = 4). The correlation coefficient of the CLEIA of AFP vs ordinary RIA was 0.972 with a slope of 0.87 (n = 28).
To compare the time course of immunoreaction between beads and ferrite particles iny, we examined the incorporation of CA19-9 antigen into 1116NS19-9 antibodies immobilized in solid support by the CLEJA method (Figure 2a) . Reaching the maximum signal took about 16 h for the bead assay, whereas the ferrite assay appeared to reach a msnnmum signal alter the immunoreaction had proceeded for 1 h. Figure 2b shows the standard curves of both the ferrite and the bead system for the two-step assay under otherwise identical conditions. The slope of the linear curve for the ferrite particles assay was about 18-fold steeper than that for the bead assay.
When we used ferrite particles as solid support, the dose-response curve for CA19-9 appeared to be linear within the working range of 0 to 240 kilo-arb. unita/L (Figure 3a) . Similar standard curves were obtained for the CA125 and CEA, with working ranges of 0 to 480 kilo-arb. units/L and 0 to 100 pg/L, respectively (data not shown). In contrast, although the standard curve for AFP (0-800 pg/L) was linear up to about 400 pg/L, after that, the slope of the curve declined (Figure 3b) . Even when the analyte concentrations were increased far beyond the dynamic range, the linearity of the standard curve was maintained, up to -4000 kilo-arb. units/L for CA19-9, 5000 kilo-arb. unmts/L for CA125, and 1000 pg/L for CEA (Figure 4) . CA159 and rapid assay system. To accomplish this, we needed a total assay time no longer than 30 mm. Regardless of analytes, we thus chose 20 min for the immunoreaction and 5 mm for the enzyme reaction, attainable with use of ferrite particles and AMPPD, and performed the following evaluations by means of the assay ibrmats described in Figure 1 .
Performance of CLEIA (Ferrite System) Precision: Analytical reproducibilities were evaluated and are listed in Table 1 . The intra-assay CVs for CA19-9, CA125, CEA, and AFP determinations with the CLEIA were between 0.8% and 5.7%; the interassay CVs were between 1.4% and 9.6%.
Linearity:
Linear correlations between measured and expected values were as follows: for CA19-9, r = 0.9999, slope = 1.000, intercept = 0.033; for CA125, r = 0.9998, slope = 0.9942, intercept Analytical recovery of the marker added to human serum ranged from 91% to 109% for all markers. Comparison with other methods: Figure 5 shows a correlation of the CLEIA with other methods (conventional EIA or RIA kits). Correlation of test results by the present CLEIA (y) with those by EIA or RIA (x) for serum samples within the range of the standard curve gave the following regression equations:
for CA19-9, y = 0.947x a solid phase, our CLEIA method with the chemiluminescent substrate AMPPD is feasible for measuring tumor markers in serum samples. The ferrite-particle system reaches the maximum signal in a much shorter time than the bead system (Figure 2a) , suggesting that the rate of an immunoreaction reaching its equilibrium in the ferrite-particle system is an order of magnitude faster than that in the bead system. As shown in Figure  2b , the signal-to-noise slope of the dose-response curves, at the time at which the immunoreaction had not reached equilibrium, reflects the assay sensitivity. Thus the bead system is also inferior to the ferrite particles system in this regard. These findings may be explained as the result of the increase in the number of immobilized antibodies available for immunoreaction to be bound to the surface of the solid support. The calculated surface area per test was 2.2 cm2 for a 0.2 g/L ferrite suspension and 1.1 cm2 for a 6-mm-diameter bead. This would enhance the binding kinetics between the antibodies attached on the ferrite surface and the antigens in the solution phase, supporting a tendency to reach the maximum binding faster. A similar phenomenon was observed when chromium dioxide was used as a solid support (17). An additional benefit to using the ferrite-coated particles is the ability to separate bound and free analyte magnetically.
In this regard our results are similar to those reported for a colorimetric immunoassay with chromium dioxide particles (17) and for a fluoroimmunoassay with magnetizable cellulose/iron oxide particles
(23).
For all analytes except for AFP, the dose-response curves appeared to be linear. In addition, these straight linear relationships are maintained up to high concentrations of the analyte, beyond the working ranges (Figure 4 ). This indicates that the CLEIA has the capacity to detect signals even from high concentrations of analytes used. In general, these observations are in contrast with those of colorimetric EIAs, in which the standard curve declined from a straight line at concentrations above the dynamic range because of the limitation of absorbance measurements. Lack of linearity in the AFP standard curve may be due not only to insufficient amounts of conjugates but also to limitations of the capture antibodies fixed on the solid phase in the reaction system. In fact, when we added much greater concentrations of the conjugates to the reaction system, the standard curve approached a straight line (data not shown); however, the curve was still not a straight one and declined with the increase in AFP concentrations, which suggests that the mass of available antibodies for immunoreaction on the solid surface is a still limiting factor.
Lower detection limits with the ferrite CLEIA (Table 2) were below the detection limits for CA19-9, CA125, and CEA by EIA or RIA (8,11). However, the most prominent increase in sensitivity was observed in the AFP assay, in which the detection limit of the CLEIA was -30-fold lower than that of the EIA. This increase in the sensitivity is probably attributable to our use not only of small particles but also of cheimluminescent substrate. An improved sensitivity similar to our result has been observed for immunoassay of AFP or choriogonadotropin when AMPPD was used in place of p-nitrophenyl phosphate as ALP substrate (14) . The relatively small increases in the sensitivity of CLEIA for the markers (except AFP) may-be attributable to the efficacy of ferrite particles in imniunoreaction being partly canceled by the presence of lower analyte concentrations. For instance, in the reaction system, the dilution of CA19-9, CA125, and CEA is 6.75, 13.5, and 7.75 times lessthan that of the RIA (8,11) or the EIA, respectively. Because the determining sensitivity (detection limit) of an immunoassay is well-recognized as the affinity of the antibody, perhaps another possibility is that the antibody affinity might be diminished as a result of immobilization on the solid phase and conjugation with a labeling enzyme.
The time required for an assay is short in CLE!A because low chemiluminescent signals can be detected after even shorter periods of enzyme reaction. In the CA125 assay, especially, the time required for the CLELA was about 2% of that for the RIA.
From a practical point of view, although colorimetric and radiometric immunoassays sufficiently cover the dynamic range of the tumor markers to be measured for clinical evaluation, these assays take a rather long time: between 30 mm and 20 h. The CLEIA, however, can cover the dynamic range in a short assay time. Moreover, as shown in Figure 4 , the CLEIA has the potential to extend the dynamic range beyond the present limitation of Elk Finally, even though the assay time is complete within 30 mm regardless of the analyte, reasonable. precision proffles and reliability of testing (analytical recovery and linearity) are obtained, making it possible to perform the CLEIA method with a fully automated system.
